The aberrant activation of Src, a typical non-receptor tyrosine kinase (nRTK), has been reported in many cancers, including lung cancer, prostate cancer, pancreatic cancer, breast cancer, and colorectal cancer [19]. This evidence concerns the gene SRC and prostate carcinoma.